Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

China's health authority has granted GSK's Blenrep blood cancer treatment with a so-called 'Breakthrough Therapy Designation' ...

GSK plc (GSK, GSK.L) said that the Center for Drug Evaluation (CDE) of the National Medical Products Administration or NMPA in China ...

Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...

China’s NMPA granted BTD for Blenrep (belantamab mafodotin) combined with BorDex for the treatment of multiple myeloma.

(Alliance News) - GSK PLC on Friday announced that it has been granted breakthrough therapy designation in China for Blenrep, a treatment for relapsed or refractory multiple myeloma. The London ...

Lingang Centre, marking its official establishment in the Lingang Investment Holding Group Park. This wholly-owned subsidiary will primarily handle two domestic products focusing on hepatitis and anti ...

(RTTNews) - GSK plc (GSK, GSK.L) said that the Center for Drug Evaluation (CDE) of the National Medical Products Administration or NMPA in China has granted Breakthrough Therapy Designation to ...

GSK’s Blenrep in combo with BorDex receives China NMPA breakthrough therapy designation to treat relapsed/refractory multiple myeloma: London, UK Saturday, September 14, 2024, 0 ...

Japan's health ministry has accepted for review a new drug application (NDA) for GSK's Blenrep blood cancer treatment, marking the third major regulatory filing acceptance for the drug.